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Abstract
Background Mutations in the ataxia-telangiectasia mutated
(ATM) and checkpoint kinase 2 (CHEK2) genes and
amplification of the v-erb-b2 avian erythroblastic leukemia viral
oncogene homolog 2 (ERBB2) gene have been suggested to
have an important role in breast cancer aetiology. However,
whether common variation in these genes has a role in the
development of breast cancer or breast cancer survival in
humans is still not clear.
Methods We performed a comprehensive haplotype analysis of
the ATM, CHEK2 and ERBB2 genes in a Swedish population-
based study, which included 1,579 breast cancer cases and
1,516 controls. We followed the cases for 8.5 years, on
average, and retrieved information on the date and cause of
death during that period from the nationwide Swedish causes of
death registry. We selected seven haplotype-tagging SNPs
(tagSNPs) in the ATM gene, six tagSNPs in the CHEK2 gene
and seven tagSNPs in the ERBB2 gene that predicted both
haplotypic and single locus variations in the respective genes
with R2 values ≥ 0.8. These tagSNPs were genotyped in the
complete set of cases and controls. We computed expected
haplotype dosages of the tagSNP haplotypes and included the
dosages as explanatory variables in Cox proportional hazards or
logistic regression models.
Results We found no association between any genetic variation
in the ATM,  CHEK2  or  ERBB2  genes and breast cancer
survival or the risk of developing tumours with certain
characteristics.
Conclusion Our results indicate that common variants in the
ATM, CHEK2 or ERBB2 genes are not involved in modifying
breast cancer survival or the risk of tumour-characteristic-
defined breast cancer.
Introduction
Twin and family studies consistently indicate that the risk of
breast cancer is influenced, in part, by hereditary factors, but
high-risk mutations seem to account for only 1–2% of all
breast cancer cases in the general population [1]. A polygenic
model has been proposed to account for the residual familial
risk [2], which anticipates small effects of several low-pene-
trance genetic risk variants in combination with environmental
influence. Although no human data exist for the affect of germ-
line polymorphisms on tumour outcome, there is strong evi-
dence that strain background is a significant determinant of
the clinical behaviour of experimental mammary carcinomas in
mice [3-5]. We thus set out to study the role of common vari-
ation in key breast cancer candidate genes in relation to breast
cancer aetiology, survival and tumour characteristics.
The ataxia-telangiectasia mutated (ATM; MIM 607585),
checkpoint kinase 2 (CHEK2; MIM 604373) and v-erb-b2
A-T = ataxia-telangiectasia; ATM = ataxia-telangiectasia mutated; CHEK2 = checkpoint kinase 2; CI = confidence interval; dbSNP = Single Nucle-
otide Polymorphism database; ERBB2 = v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; HWE = Hardy–Weinberg equilibrium; kb 
= kilobase; LD = linkage disequilibrium; OR = odds ratio; SNP = single nucleotide polymorphism; tagSNP = haplotype-tagging SNP.Breast Cancer Research    Vol 8 No 6    Einarsdóttir et al.
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avian erythroblastic leukemia viral oncogene homolog 2
(ERBB2; also named HER2; MIM 164870) genes have been
suggested to have an important role in breast cancer aetiol-
ogy. The ATM protein is activated in response to ionizing radi-
ation and triggers phosphorylation of CHEK2 and other
proteins that promote cell cycle arrest and activation of DNA
repair [6-12]. The ATM gene is mutated in the rare autosomal
recessive disorder ataxia-telangiectasia (A-T) and the risk of
breast cancer has been found to be increased in relatives of
A-T patients [13,14], in addition to A-T heterozygotes [15,16].
Mutations in the CHEK2 gene have been found in patients
with Li-Fraumeni syndrome [17] and one such mutation – the
rare 1100delC gene mutation – has been found to increase
breast cancer susceptibility at the population level [18] and in
families without BRCA1 or BRCA2 gene mutations [19,20].
ERBB2 is a transmembrane glycoprotein, with tyrosine kinase
activity [21-25], that has a major role in signal transduction,
thereby affecting cell proliferation, differentiation, motility and
survival [26-28]. The ERBB2 gene is amplified and/or over-
expressed in approximately 30% of breast tumours, a phenom-
enon that is associated with a poor prognosis [29-31].
Until now, common variation in the ATM, CHEK2 and ERBB2
genes has mainly been studied in relation to the overall risk of
breast cancer, but the results have been inconclusive. It is
worthwhile studying common variation in the ATM, CHEK2
and ERBB2 genes in relation to breast cancer progression
because defects in the genes could increase the risk of devel-
oping tumours with an unfavourable prognosis through their
role in the regulation of cell cycle checkpoints and amplifica-
tion. Variation in the genes could also affect cancer survival
through increased radiosensitivity [32-34]. One group found a
relationship between poor breast cancer prognosis and com-
mon haplotypes in the ERBB2 gene [35], but to our knowl-
edge, nothing has been reported regarding the association
between common haplotypes in the ATM and CHEK2 genes
and breast cancer survival or tumour characteristics. Hence,
many questions regarding the role of these genes in breast
cancer survival and the progression of breast cancers are
unanswered.
We performed a haplotype analysis of the ATM, CHEK2 and
ERBB2 genes by genotyping a dense set of markers in each
gene in 92 randomly selected controls, thus acquiring a com-
prehensive coverage of the common variation in each entire
gene. We genotyped selected haplotype-tagging SNPs (tag-
SNPs) in a well-defined, Swedish population. We then
assessed the association of the tagSNPs in the ATM, CHEK2
and ERBB2 genes and their haplotypes with breast cancer
survival and the risk of tumour-characteristic-defined breast
cancer. We also studied the tagSNPs and haplotypes in the
ATM and ERBB2 genes, in addition to two mis-sense muta-
tions in the ATM gene (2572 T→C and 4258 C→T), in rela-
tion to the overall risk of breast cancer.
Materials and methods
Study population
The study base included all Swedish-born women between 50
and 74 years of age who were resident in Sweden between
October 1993 and March 1995. During that period, we iden-
tified all breast cancer cases at diagnosis through the six
regional cancer registries in Sweden, which provide virtually
complete data on incident cancers in Sweden [36]. We ran-
domly selected controls, who matched the cases in 5-year age
strata, from the Swedish registry of the total population. Of the
eligible women, 3,345 (84%) breast cancer cases and 3,454
(82%) controls participated in this initial questionnaire-based
study, providing detailed information on their use of menopau-
sal hormone therapy, their reproductive history and other life-
style factors. Results from the study have been published [37-
41].
From this initial study, we randomly selected 1,500 breast can-
cer cases and 1,500 age–frequency-matched controls among
the postmenopausal participants without any previous malig-
nancy (except carcinoma in situ of the cervix or nonmelanoma
skin cancer). With the intention of increasing the statistical
power in subgroup analyses, we further selected all of the
remaining breast cancer cases and controls who had used
menopausal hormones (oestrogen alone or any combination of
oestrogen and progestin) for at least 4 years (191 cases and
108 controls) and all women with self-reported diabetes mel-
litus (110 cases and 104 controls). Additionally, 345 controls,
who were included in both the initial breast cancer study and
an endometrial cancer study with the same study base and
inclusion criteria, were added to the control group. In total, we
selected 1,801 breast cancer cases and 2,057 controls.
After informed consent was obtained, participants donated
whole blood. For deceased breast cancer patients and women
who declined to donate blood but consented to the use of tis-
sue samples, we collected archived paraffin-embedded, non-
cancerous tissue samples. We acquired 70% of the
requested tissue samples; the main reason for nonparticipa-
tion was unwillingness or a lack of time at the respective
pathology department to provide the tissue blocks. In total, we
obtained 1,321 blood samples and 275 archived tissue sam-
ples from the breast cancer patients and 1,524 blood samples
from the controls. The mean time from diagnosis to the arrival
of the blood and tissue samples at our department was 5
years. Reasons for nonparticipation included a lack of interest
in research, a negative attitude towards genetic research, old
age and severe disease or death. Population-based participa-
tion rates (taking into account the proportion of individuals
who did not participate in the questionnaire-based study) for
the breast cancer cases and controls were 75% and 61%,
respectively.
This study was approved by the Institutional Review Boards in
Sweden and the National University of Singapore.Available online http://breast-cancer-research.com/content/8/6/R67
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DNA isolation
The Swegene laboratories in Malmö (Sweden) extracted DNA
from 4 ml of whole blood using the QIAamp DNA Blood Maxi
Kit (Qiagen, Solna, Sweden) according to the manufacturer's
instructions. From nonmalignant cells in paraffin-embedded
tissue, we extracted DNA using a standard phenol/chloroform/
isoamyl alcohol protocol [42]. We successfully isolated DNA
from 1,318 blood samples and 272 tissue samples from the
breast cancer patients and 1,518 blood samples from the
controls.
SNP markers and genotyping
The ATM  gene covers 146.3 kb of genomic sequence on
chromosome 11, the CHEK2 gene spans 54.1 kb on chromo-
some 22 and the ERBB2 gene covers 33.7 kb on chromo-
some 17 (build 125 in the dbSNP (Single Nucleotide
Polymorphism database). We selected SNPs in the ATM,
CHEK2  and  ERBB2  genes and their 10 kb flanking
sequences from dbSNP (build 124) and Celera databases
aiming for an initial marker density of at least one SNP per 5
kb. SNPs were genotyped using the Sequenom primer exten-
sion-based assay (San Diego, CA, USA) and the BeadArray
system (Illumina, San Diego, CA, USA) according to the man-
ufacturers' instructions. All genotyping results were generated
and checked by laboratory staff unaware of case–control sta-
tus. Only SNPs for which >85% of the samples gave a geno-
type call were analysed further. As a quality control, we
genotyped 200 randomly selected SNPs (not including SNPs
in the ATM, CHEK2 or ERBB2 genes) in the 92 control sam-
ples using both the Sequenom system and the BeadArray sys-
tem. The genotype concordance was >99.5%, suggesting
high genotyping accuracy.
Characterization of linkage disequilibrium and 
haplotype-tagging SNP selection
We produced linkage disequilibrium (LD) plots of the D' values
for ATM and ERBB2 genes (supplementary Figures 1 and 2,
respectively) using the Haploview program [43]. We recon-
structed haplotypes for all three genes using the partition-liga-
tion-expectation-maximization (PLEM) algorithm [44]
implemented in the tagSNPs program [45] and selected tag-
SNPs according to the R2 coefficient, which quantifies how
well the tagSNP haplotypes predict the SNPs or the number
of copies of haplotypes that an individual carries. We chose
tagSNPs so that common SNP genotypes (minor allele fre-
quency  ≥0.03) and common haplotypes (frequency ≥0.03)
were predicted by R2 values ≥ 0.8 [46]. To evaluate the per-
formance of our tagSNPs in capturing unobserved SNPs
within the genes and to assess whether a denser set of mark-
ers was needed, we performed a SNP-dropping analysis
[47,48]. In brief, each of the genotyped SNPs was dropped in
turn and tagSNPs were selected from the remaining SNPs so
that their haplotypes predicted the remaining SNPs with an R2
value of 0.85. We then estimated how well the tagSNP haplo-
types of the remaining SNPs predicted the dropped SNP, an
evaluation that can provide an unbiased and accurate estimate
of tagSNP performance [47,48].
Tumour characteristics and follow-up
We retrieved information on the date and cause of death (until
31 December 2003) from the Swedish causes of death regis-
try and the date of emigration from the Swedish national pop-
ulation registry. Information from the causes of death registry
in Sweden has been found to be of high quality [49]. The fol-
low-up time began at the date of diagnosis and ended on 31
December 2003 or at the date of death or emigration, which-
ever came first. We collected information on tumour character-
istics, such as tumour size, lymph-node involvement, grade
(tumour differentiation), histological type and date of the first
distant metastasis, from medical records. We obtained infor-
mation on the oestrogen and progesterone receptor content
and S-phase fraction (i.e. the proportion of tumour cells in the
DNA synthesis phase of the cell cycle) of the tumours from
seven laboratories around Sweden that routinely perform
these tumour measurements for the whole country. At the time
of the study, all seven laboratories used an enzyme immu-
noassay (Abbott Laboratories, Solna, Sweden) on cytosol
samples for analysing the oestrogen and progesterone recep-
tor content. This method was oestrogen receptor type α spe-
cific [50]. The laboratories reported either quantitative
measurements (fmol receptor per μg DNA or mg protein and
the percentage of cells in S-phase) or categorical measure-
ments (strongly positive, positive, weakly positive or negative
for receptor status and high, intermediate or low S-phase frac-
tion). A rather high proportion of this information was missing,
which was owing to the fact that these measurements were
not routinely performed in the mid-1990s. We classified the
tumour characteristics as follows:
1. TNM stage:
1.a. Stage 1 – tumour size ≤20 mm and no regional lymph-
node metastases.
1.b. Stage 2 – tumour size ≤20 mm and lymph-node metas-
tases, or tumour size 20–≤50 mm, or tumour size >50 mm and
no lymph-node metastases.
1.c. Stage 3 – an inflammatory breast tumour, or tumour size
>50 mm and lymph-node metastases.
1.d. Stage 4 – distant metastasis within 90 days of diagnosis.
2. Lymph-node involvement:
2.a. Yes – at least one metastasised lymph node.
2.b. No – no metastasised lymph node.
3. Grade:Breast Cancer Research    Vol 8 No 6    Einarsdóttir et al.
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3.a. High differentiation.
3.b. Intermediate differentiation.
3.c. Low differentiation.
4. Oestrogen and progesterone receptor status:
4.a. Positive – ≥0.05 fmol/μg DNA, ≥10 fmol/mg protein or
categorically strongly positive, weakly positive or positive.
4.b. Negative – <0.05 fmol/μg DNA, <10 fmol/mg protein or
categorically negative.
5. S-phase fraction:
5.a. High – ≥9% or categorically high.
5.b. Low – <9% or categorically low.
We combined TNM stage 3 and TNM stage 4 in all associa-
tion analyses because of small numbers.
Statistical analyses
In assessing the association with tumour-characteristic-
defined breast cancer, we stratified the cases on breast can-
cer subtypes and compared each group with the controls. Our
testing strategy was to fit a single model and assess within
each stratum of risk-factor subgroup and for different tumour
characteristics, haplotype-trait associations as a global likeli-
hood ratio test [51]. We first computed expected haplotype
dosage using the tagSNPs program [45], with haplotype fre-
quencies estimated for the breast cancer cases and controls
combined, assuming Hardy–Weinberg equilibrium (HWE) of
haplotypes. We then, included the haplotype dosages as
explanatory variables in the regression models. To estimate the
power in the risk component of the study, we used a method
described by Chapman and colleagues [52], which assumes
co-dominant effects at an unobserved locus. To calculate the
power for log-additive effects in the survival component of the
study, we used the Quanto program [53] in a similar manner
to that described by Manolio and colleagues [54].
We applied unconditional logistic regression models adjusted
for age (in 5-year age-groups) to assess the relationship
between the ATM, CHEK2 and ERBB2 tagSNP haplotypes
and the overall risk of breast cancer, in addition to breast can-
cer subtypes. We estimated the hazard ratio of death owing to
breast cancer in relation to the genes' tagSNP haplotypes
using Cox proportional hazards models. The appropriateness
of these approaches is supported by Stram and colleagues
[45]. That is, if R2 values are high, such as here, the point and
interval estimates obtained by this approach will be approxi-
mately accurate. To assess the proportional hazards assump-
tions of the Cox models, we examined scaled Schoenfeld
residuals and found no evidence against proportionality.
'Confounding' has been defined as the presence of a common
cause of the exposure and outcome [55]. We believe that life-
style and reproductive breast cancer risk factors are unlikely to
cause genetic variation in the genes, but they could be inter-
mediates in the causal pathway between the genes and both
breast cancer and tumour-characteristic-defined breast can-
cer. For completeness, we assessed whether the tagSNPs
were associated with known breast cancer risk factors (age at
menarche, age at menopause, body mass index, age at first
birth, parity, menopausal hormone use and diabetes mellitus)
among the randomly selected controls using Kruskal-Wallis
and Chi square tests. Analyses were performed using the SAS
system (release 9.1; SAS Institute Inc., Cary, NC, USA).
Results
Study population
Characteristics of breast cancer cases in the parent case–
control study and the current genetic association study are
described in Table 1. With respect to nongenetic factors
among cases and controls [56] and tumour characteristics
among cases (Table 1), the current study was representative
of the parent study. Breast-cancer-specific death rates among
the cases in the current study reflected known prognostic
information on various tumour characteristics (Table 1).
Tumours with unknown hormone receptor status or S-phase
fraction were smaller in both parent and current studies (P <
0.0001 for both receptor status and S-phase fraction). Miss-
ing information on tumour grade depended significantly on
tumour size in the parent study (P = 0.01) but not in the cur-
rent study (P = 0.15).
Cases who participated through tissue sample donation were,
on average, 1.5 years older (P = 0.0003) and more likely to
have been diagnosed with TNM stage 2 or more advanced
cancers (P < 0.0001) compared with cases who donated a
blood sample. Importantly, no significant differences in the
genotype frequencies were evident between cases who par-
ticipated through blood or tissue sample donation.
Estimation of the pattern of linkage disequilibrium and 
coverage
We summarize the statistics for the genotyping results and
SNP coverage in the ATM, CHEK2 and ERBB2 genes in sup-
plementary Table 1. The SNPs in the ATM,  ERBB2  and
CHEK2 genes that were successfully genotyped in 92 ran-
domly selected controls are listed in supplementary Table 2
(ATM) and 3 (ERBB2), and have been previously published in
Table 2 by Einarsdóttir and colleagues [56] (CHEK2). In brief,
our study included 51 SNPs in the ATM gene, 14 SNPs in the
CHEK2 gene and 13 SNPs in the ERBB2 gene that were suc-
cessfully genotyped – and were in HWE – in the 92 controls.
The mean spacing between the SNPs included in our studyAvailable online http://breast-cancer-research.com/content/8/6/R67
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Table 1
Characteristics of the breast cancer cases in the parent study and the present genetic study
Parent study Present study Present study
Characteristic n (%) n (%) Breast cancer deathsa Mortality rateb
Total cases 2,817 1,579 198 0.016
Tumour size (mm)
≤20 1,858 (71.4) 1,087 (73.6) 100 0.010
21–30 489 (18.8) 270 (18.3) 57 0.026
>30 254 (9.8) 120 (8.1) 38 0.043
Unknown 216 102 3 0.022
P valuec 0.13
TNM stage
1 1,392 (54.4) 804 (55.3) 40 0.006
2 1,074 (42.0) 606 (41.7) 126 0.026
3 58 (2.3) 31 (2.1) 15 0.076
4 34 (1.3) 12 (0.8) 11 0.262
Unknown 259 126 6 0.019
P valuec 0.39
Lymph-node involvement
No 1,741 (68.2) 1,002 (68.9) 68 0.008
Yes 813 (31.8) 453 (31.1) 122 0.035
Unknown 263 124 8 0.027
P valuec 0.23
Grade
1 259 (14.7) 143 (14.2) 4 0.003
2 739 (41.9) 444 (44.1) 37 0.010
3 766 (43.4) 419 (41.7) 93 0.027
Unknown 1,053 573 64 0.016
P valuec 0.61
Oestrogen and progesterone receptor status
ER+/PR+ 1,162 (62.7) 677 (65.4) 72 0.012
ER+/PR- 285 (15.4) 133 (12.9) 28 0.026
ER-/PR+ 69 (3.7) 33 (3.2) 7 0.027
ER-/PR- 338 (18.2) 192 (18.6) 52 0.037
Unknown 963 544 39 0.010
P valuec 0.37
Histological type
Ductal 1,891 (72.5) 1,070 (72.4) 147 0.016
Lobular 304 (11.7) 185 (12.5) 19 0.012
Other 414 (15.9) 223 (15.1) 28 0.014
Unknown 208 101 4 0.039
P valuec 0.48
S-phase fraction
Low 689 (68.1) 401 (70.0) 40 0.011
High 323 (31.9) 172 (30.0) 52 0.040
Unknown 1805 1,006 106 0.013
P valuec 0.71
aFrom the date of diagnosis until 31 December 2003.
bFrom the date of diagnosis until 31 December 2003 or until the date of death or emigration, whichever came first. Calculated as breast cancer 
deaths per person-year of follow-up.
cChi-squared test of independence between the parent and the present studies.
ER, oestrogen receptor; PR, progesterone receptorBreast Cancer Research    Vol 8 No 6    Einarsdóttir et al.
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was 2.9 kb in the ATM gene, 4.0 kb in the CHEK2 gene and
2.8 kb in the ERBB2 gene. We detected strong LD across all
three genes [supplementary Figure 1, Figure 1 in Einarsdóttir
and colleagues [56] and supplementary figure 2, respectively].
Using the SNP dropping method [47], we found that the tag-
SNPs selected from the SNPs included in our study could
capture nongenotyped SNPs as efficiently as the SNPs
included in our study (supplementary Table 1).
Breast cancer survival
Table 2 summarizes the information on the tagSNPs in the
ATM, CHEK2 and ERBB2 genes that we genotyped in breast
cancer cases and controls. All of the tagSNPs in the CHEK2
and ERBB2 genes and two of the tagSNPs in the ATM gene
were not only genotyped in breast cancer cases and controls
who participated through blood sample donation, but were
also genotyped in breast cancer cases who participated
through tissue sample donation. None of the tagSNPs devi-
ated significantly from HWE among the controls or showed a
meaningful association with known breast cancer risk factors.
Only one of the tagSNPs – TAG5 (also named I655V) in the
ERBB2 gene – conferred an amino acid change in the protein
product.
We estimated the risk of death from breast cancer associated
with the tagSNPs (Table 2) in the ATM, CHEK2 and ERBB2
genes or their haplotypes (Table 3). We found a decreased
risk of death from breast cancer associated with each addition
of the rare TAG2 allele in the CHEK2 gene (P = 0.026) and
an elevated risk of death from breast cancer associated with
the rare TAG6 allele in the CHEK2 gene (P = 0.03), compared
with homozygotes of the common allele for each variant. The
associations did not, however, withstand Bonferroni correc-
tion. Carriers of haplotype 2 in the CHEK2 gene seemed to
have a decreased risk of death from breast cancer (P = 0.038)
compared with haplotype 1 carriers, whereas carriers of the
rare ERBB2 haplotypes seemed to have an increased risk of
death from breast cancer (P = 0.009). Neither association car-
ried over to the global test (P  = 0.15 and P  = 0.45,
respectively).
We noticed in Table 3 that all of the ATM haplotypes con-
ferred a decrease in risk of death from breast cancer com-
pared with haplotype 1. We therefore assessed the
association of haplotype 1 with the risk of death from breast
cancer and found a nonsignificantly elevated risk compared
with noncarriers [odds ratio (OR), 1.13; 95% confidence inter-
val (CI), 0.92–1.40].
Tumour characteristics
We calculated global P values for the association between the
tagSNP haplotypes in the ATM, CHEK2 and ERBB2 genes
and the risk of tumour-characteristic-defined breast cancer
from logistic regression models. Cases were divided into
groups according to their tumour characteristics and each
group contrasted against all controls. Each logistic regression
model included the common haplotypes and the combined
group of rare haplotypes, with the most common haplotype
used as a reference standard. None of the global P values
reached significance (supplementary Table 4), which indi-
cates that none of the individual haplotypes affected the risk of
developing tumours with certain characteristics.
We genotyped the CHEK2 1100delC gene mutation in our
study population and have previously reported its effect on the
overall risk of breast cancer [56]. The deletion was very rare in
our study population, with a frequency of 0.7% among the
cases and 0.4% among the controls. We could therefore not
perform a meaningful analysis of the association between the
deletion and breast cancer characteristics or survival in the
current study.
Overall risk of breast cancer: the ATM and ERBB2 genes
We found no effect of the ATM or ERBB2 tagSNPs (supple-
mentary Table 5) or haplotypes (supplementary Table 6) on
the overall risk of breast cancer, which was not altered after
conditioning on the selection variables (menopausal hormone
therapy and diabetes mellitus) or restricting the analyses to the
randomly selected cases and controls. Stratifying the haplo-
type results by known breast cancer risk factors did not yield
any additional compelling findings (supplementary Table 7).
We genotyped two mis-sense mutations in the ATM gene in
the complete sample set: 4258 C→T (rs1800058; L1420F)
and 2572 T→C (rs1800056; F858L). Neither mutation devi-
ated significantly from HWE in controls. They were both rare
in our study population, with a minor allele frequency of 1.9%
for 4258 C→T and 1.4% for 2527 T→C in the controls. In
exploring the change in the risk of breast cancer with each
addition of the rare allele compared with noncarriers (assum-
ing co-dominance), an elevated – but not significant – risk for
the 4258 C→T (OR, 1.36; 95% CI, 0.91–2.04) was found,
but no association emerged between the 2527 T→C and the
risk of breast cancer (OR, 1.05; 95% CI, 0.65–1.71).
Discussion
Although the gene products of ATM, CHEK2 and ERBB2 are
involved in various aspects of breast cancer development and
progression, our results suggest that common variation in
these genes does not affect survival, tumour-characteristic-
defined risk or the overall risk of breast cancer. We carefully
studied these associations, both overall and in subgroups of
known nongenetic breast cancer risk factors, using large pop-
ulation-based case–control material, and conclude that on the
population level, common genetic variation in these genes is
not of great importance for these outcomes. This does not pre-
clude the possibility that more crucial – and rare – variation is
influential in selected patient groups.Available online http://breast-cancer-research.com/content/8/6/R67
Page 7 of 12
(page number not for citation purposes)
Our study was population-based. All participants were born in
Sweden between 1919 and 1944, a time at which foreign
immigration to Sweden was still rare [57], which means popu-
lation stratification is of limited concern in our study. To mini-
mize exposure misclassification, we applied genotyping
methods with low error rates (the Sequenom and Illumina
methods have genotyping error rates of 0.5% and 0.3%,
respectively), DNA samples were randomly assigned to the
genotyping plates and the genotyping personnel were blinded
to case–control status. Furthermore, we replicated genotype
calls of 200 randomly selected SNPs for a subset of samples
using a separate genotyping method with >99.5%
concordance.
The oestrogen and progesterone receptor status of tumours
and S-phase fraction were assessed at seven different labora-
tories in Sweden, but it is doubtful that the genotype frequen-
cies could be related to any interlaboratory differences. A large
proportion of the information on receptor status, S-phase frac-
tion and grade was missing. Assessment of receptor status
and S-phase fraction was, to a large extent, dependent on the
size of the tumour, but evaluation of the tumour grade was
Table 2
Characteristics of the ATM, CHEK2 and ERBB2 tagSNPs and their association with breast cancer survival
SNP ID SNP name Number of cases/
controls
Minor allele 
frequencya
Breast cancer deaths/
person-yearsb
HR (95% CI)b,c
ATM
TAG1d rs4987886 1,220/1,440 0.06 70/10,660 0.86 (0.42–1.76)
TAG2d rs3092991 1,119/1,318 0.14 65/9,717 1.12 (0.71–1.77)
TAG3d rs1800057 1,144/1,346 0.03 66/9,958 0.62 (0.16–2.46)
TAG4 rs1801516 1538/1,500 0.15 185/12,421 0.99 (0.75–1.30)
TAG5 rs17107917 1,546/1,493 0.04 192/12,466 1.01 (0.63–1.64)
TAG6d rs227060 1,152/1,350 0.28 68/10,004 0.77 (0.52–1.14)
TAG7d rs664143 1,227/1,408 0.48 73/10,684 1.24 (0.89–1.73)
CHEK2
TAG1 rs8135424 1,539/1,478 0.13 197/12,367 1.08 (0.83–1.41)
TAG2 rs5762749 1,516/1,472 0.35 191/12,172 0.78 (0.62–0.97)
TAG3 rs743185 1,547/1,491 0.12 192/12,471 1.21 (0.91–1.62)
TAG4 rs738722 1,501/1,444 0.25 187/12,083 0.72 (0.56–0.93)
TAG5 rs5762765 1,510/1,456 0.38 192/12,118 1.15 (0.94–1.41)
TAG6 rs2236142 1,541/1,471 0.31 192/12,398 1.25 (1.02–1.54)
ERBB2
TAG1 rs2643195 1,494/1,458 0.32 186/12,052 1.09 (0.88–1.35)
TAG2 rs4252596 1,530/1,481 0.13 189/12,330 0.95 (0.70–1.30)
TAG3 rs2952155 1,459/1,407 0.25 184/11,666 1.02 (0.80–1.29)
TAG4 rs2952156 1,546/1,481 0.32 194/12,445 1.11 (0.89–1.37)
TAG5e rs1801200e 1,548/1,485 0.26 193/12,463 1.00 (0.80–1.25)
TAG6 rs4252665 1,527/1,486 0.05 182/12,401 0.76 (0.45–1.27)
TAG7 rs3809717 1,532/1,478 0.31 194/12,310 0.96 (0.77–1.20)
aIn controls.
bAmong women with breast cancer.
cHRs are assessed assuming co-dominance and show the increase/decrease in risk of death from breast cancer with each addition of the minor 
allele compared with homozygotes of the major allele.
dNot genotyped in the patients who participated through tissue sample donation.
eAlso named I655V.
ATM, ataxia-telangiectasia mutated; CHEK2, checkpoint kinase 2; CI, confidence interval; ERBB2, v-erb-b2 avian erythroblastic leukemia viral 
oncogene homolog 2; HR, hazard ratio; SNP, single nucleotide polymorphism; tagSNP, haplotype-tagging SNP.Breast Cancer Research    Vol 8 No 6    Einarsdóttir et al.
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mostly dependent on the pathologist's decision. Because gen-
otype frequencies were not related to tumour size, bias owing
to the missing information on these factors seems unlikely.
Survival bias could be a concern in our study because nonpar-
ticipation was related to severe disease or death. However, we
obtained the majority of the tissue samples requested for
Table 3
tagSNP haplotypes in the ATM, CHEK2 and ERBB2 genes in relation to breast cancer survival
Haplotype no. Haplotypes Haplotype proportions (cases) HR (95% CI)
ATM n = 1,574a
1 AACGCCT 0.414 1.00 (Reference)
2 AACGCTC 0.231 0.85 (0.65–1.13)
3 AGCACCC 0.150 0.89 (0.66–1.21)
4 AACGCCC 0.062 0.86 (0.52–1.44)
5 TACGCCT 0.064 0.88 (0.55–1.40)
6 AACGGTC 0.043 0.95 (0.57–1.57)
Rareb 0.037 0.95 (0.53–1.68)
Global P valuec 0.95
CHEK2 n = 1,571a
1 GCCCCC 0.223 1.00 (Reference)
2 GGCTGC 0.231 0.72 (0.52–0.98)
3 GCCCCG 0.140 1.02 (0.72–1.43)
4 ACCCGC 0.113 1.00 (0.70–1.41)
5 GCTCGG 0.089 1.08 (0.73–1.57)
6 GGCCGC 0.052 0.61 (0.34–1.10)
7 GCCCGC 0.027 0.60 (0.26–1.41)
Rared 0.125 0.95 (0.67–1.35)
Global P valuec 0.15
ERBB2 n = 1,579a
1 GGCGACT 0.296 1.00 (Reference)
2 AGTAACG 0.166 0.98 (0.71–1.34)
3 GGCGGCG 0.135 1.01 (0.73–1.40)
4 GACGACG 0.116 0.98 (0.69–1.39)
5 AGTAGCG 0.075 1.21 (0.81–1.81)
6 AGCAACG 0.068 1.16 (0.76–1.77)
7 GGCGACG 0.079 1.06 (0.69–1.63)
8 GGCGGTG 0.048 0.81 (0.47–1.39)
Raree 0.018 2.21 (1.22–4.02)
Global P valuec 0.45
aInformation on at least one tagSNP.
b11 rare haplotypes combined. Each haplotype has frequency <3% among the controls.
cProbability ratio test.
d19 rare haplotypes combined. Each haplotype has frequency <3% among the controls.
e19 rare haplotypes combined. Each haplotype has frequency <3% among the controls.
ATM, ataxia-telangiectasia mutated; CHEK2, checkpoint kinase 2; CI, confidence interval; ERBB2, v-erb-b2 avian erythroblastic leukemia viral 
oncogene homolog 2; HR, hazard ratio; tagSNP, haplotype-tagging SNP.Available online http://breast-cancer-research.com/content/8/6/R67
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deceased patients with breast cancer or breast cancer cases
who had declined donation of a blood sample. The lack of tis-
sue accessibility is unlikely to be related to ATM, ERBB2 or
CHEK2 genetic variation because it depended on the inability
of the respective pathology department to retrieve the sam-
ples. The genotype frequencies of the tagSNPs in the ERBB2
and CHEK2 genes did not differ between blood and tissue
samples, suggesting that the survival bias was negligible. We
were not able to genotype TAG1, TAG2, TAG3, TAG6 and
TAG7 in the ATM gene in the tissue samples, but because the
results were not different in the analyses restricted to the most
severe cases among those who donated blood samples indi-
cates that this was not a major problem in our study.
The loss of power from testing SNPs indirectly is thought to be
related to the R2 measure [46,58], but exceptions to these
assumptions have been reported [59]. We assessed the capa-
bility of the tagSNPs to convey an association signal from
unobserved, in addition to observed, SNPs. We captured the
unobserved SNPs with average R2 values of 0.92, 0.72 and
0.93 in the ATM, ERBB2 and CHEK2, genes, respectively,
and thus suffered minimal loss of power owing to indirect test-
ing. We performed standard power calculations assuming α =
0.05, thus giving an indication regarding the general power of
our study. We acknowledge, however, that the power is
reduced in the subgroup analyses (an effect cannot be
excluded in the smallest groups) and at lower α-levels
(required when multiple tests are carried out). For the ability of
haplotypes to predict the allele count at a causal locus with a
minor allele frequency of 0.20, we had 89% power for ATM,
73% power for ERBB2 and 87% power for CHEK2 to detect
an odds ratio of 1.3 in the risk component of the study. To
detect a hazard ratio of 1.4, with an α-level of 0.05, in the sur-
vival component of the study, we had 50% power for TAG1 in
CHEK2, which had a minor allele frequency of 0.13, and 76%
power for TAG5 in CHEK2, which had a minor allele fre-
quency of 0.38.
Our data did not support an association between common var-
iation in the ATM, CHEK2 and ERBB2 genes and breast can-
cer survival or the risk of developing tumours of different
characteristics. Hence, we did not confirm the finding of Han
and colleagues who found that an ERBB2 haplotype com-
posed of two nonsynonymous tagSNPs – I655V and P1170A
– increased the risk of breast cancer death or recurrence [35].
We included the I655V as a tagSNP in our study and geno-
typed the P1170A in the 92 controls. We found no effect of
the I655V on breast cancer survival or tumour characteristics
defined breast cancer.
To our knowledge, no study has investigated ATM or CHEK2
common haplotypes in relation to breast cancer survival or
tumour characteristics, although one study explored the effect
of three common polymorphisms in ATM and two polymor-
phisms in CHEK2 on breast cancer survival [60]. This study
found no association, which is in agreement with our findings.
The rare 1100delC mutation in the CHEK2 gene has been
associated with breast tumours of high grade [61], in addition
to steroid receptor-positive breast tumours, but not with over-
all survival [62]. The mutation was too rare in our study popu-
lation to be investigated in relation to breast cancer survival or
tumour characteristics.
We previously found no association between common varia-
tion in the CHEK2 gene and overall risk of breast cancer [56],
which was in agreement with earlier findings [63]. In this study,
we, correspondingly, found no effect of common variation in
the ATM or ERBB2 genes on the risk of breast cancer, even
when the results were stratified by known breast cancer risk
factors. One study of the ATM gene [64] and two studies of
the ERBB2 gene [35,65] are in agreement with our findings.
Tamimi and colleagues found no association between the hap-
lotypes of five Hapmap tagSNPs (one of which was TAG7 in
our study) in the ATM gene and the risk of breast cancer [64].
Benusiglio and colleagues explored ERBB2 haplotypes com-
posed of five tagSNPs [three of which were TAG2, TAG3 and
TAG5 in our study] – including the nonsynonymous I655V and
P1170A – in relation to the risk of breast cancer [65], whereas
Han and colleagues solely studied the I655V and P1170A as
tagSNPs [35]. Neither study found any effect of the haplo-
types on the risk of breast cancer. Common haplotypes in the
ERBB2 gene thus do not seem to affect the risk of breast can-
cer, although results regarding the I655V common variant in
the ERBB2 gene have been conflicting [35,65-67]. We found
no association of the I655V with the risk of breast cancer.
Three groups have found an association between specific
ATM common haplotypes and the risk of breast cancer [68-
70]. Lee and colleagues [70] and Koren and colleagues [68]
reconstructed haplotypes in the ATM gene from five and eight
randomly selected common SNPs, respectively, whereas
Angele and colleagues [69] included 11 common SNPs in the
ATM gene for their haplotype estimation that had been either
previously reported in the literature or detected by sequenc-
ing. SNP selection overlapped somewhat between the three
studies, but none of them reported the probability of their
SNPs being able to predict underlying variation in the gene.
Furthermore, findings from two of the three groups [68,69]
were derived from small sample sizes.
The 4258 C→T and 2527 T→C mutations in the ATM gene
have been detected in breast cancer patients [69,71-73], but
to the best of our knowledge, these mutations have not been
reported in A-T patients. In line with two [69,72] out of three
reports [69,71,72], we found an elevated – but not significant
– risk of breast cancer in carriers of the rare 4258 T allele in
the ATM gene. We did not, however, find such an association
in carriers of the 2527 C allele. One study found a twofold
increase in the risk of breast cancer that was related to the
2527 T→C mutation in a population from USA, but did notBreast Cancer Research    Vol 8 No 6    Einarsdóttir et al.
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confirm the finding in a Polish population [73]. Three other
groups did not detect any significant effect of the 2527 T→C
mutation on the risk of breast cancer [69,71,72], although one
of the groups found elevated point estimates [72].
Although the 4258 C→T and 2527 T→C mis-sense variants
do not seem to target residues known to be crucial for the
function of the ATM protein [72], an increasing amount of evi-
dence suggests that mis-sense variants in the ATM  gene
cause chromosomal instability and abolish the radiation-
induced kinase activity of ATM [74]. Mutant ATM protein also
seems to interfere with normal ATM function in a dominant-
negative manner [74]. Previous mutation screening studies
have indicated that mis-sense mutations in the ATM gene –
rather than protein-truncating mutations – are over-repre-
sented in patients with breast cancer compared with the gen-
eral population [72,75-79]. A recent publication refuted this
and found that ATM gene mutations that cause A-T – that is,
truncating, splicing and mis-sense mutations – are breast can-
cer susceptibility alleles [80]. They found a greater than two-
fold increase in the risk of breast cancer related to a
combination of 12 mutations, including six truncating muta-
tions [80]. Thus, controversy remains both regarding which
type of mutations in the ATM gene are involved in breast can-
cer aetiology and which mutations actually drive the associa-
tion with the risk of breast cancer [69-73,81-85].
Conclusion
Our study had a sound epidemiological design and a compre-
hensive coverage of SNPs. The results indicate that common
variation in the ATM, CHEK2 or ERBB2 genes does not have
a role in breast cancer aetiology or progression.
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